Swiftpharma
ActiveSummary
The computed 12-month bankruptcy probability of Swiftpharma is 2.0% (moderate). The annual accounts of Swiftpharma for financial year 2025 show a net loss of 68% of the equity at the start of that year. The 2025 annual accounts show equity of €834,755 and a net result of -€1.8m. Equity is growing by about 46% per year across the filed financial years. Its solvency ranks better than 24% of 9,771 sector peers (NACE 46, financial year 2025). The company has been active since 2022 and the Belgian Official Gazette contains no insolvency or warning signals.
Register details
If you follow this company, Checked tells you the day it leaves the Peppol register.
Register as of 27 October 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.
Environmental permits: No permit applications found in Flanders. Brussels and Wallonia do not publish the applicant.
Sites & property
1 establishment unit
1 parcel
| Cadastral parcel | Region | Area | Buildings | Height / floors |
|---|---|---|---|---|
| 71303B1298/00W004 | Flanders | 2.3 ha | 1 · 1,622 m² | 18.3 m · 2 |